15 Posts You Should Not Miss From The 1st Day of ESMOGI24
ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024, as well as online, through a dedicated virtual platform. The congress will be the place to present impactful new data in GI oncology.
Our team at OncoDaily has compiled a list of posts from the 1st day of this conference that you should not miss!
Welcome to ESMOGI24! Opening Press Conference covering very hot topics:
- Early onset GI cancer increasing
- Screening important to cure more GI cancer
- Making the best of our treatments
Education plus research in GI cancers coming together in Munich.
Germline mutations are common in non-familial pancreatic cancer.
Lifetime pancreatic cancer risk by gene
Screening in high-risk individuals?
No standard method .
Imaging may be used alternatingly, Ca19-9?
177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs.
Great summary of biliary tract cancer and gene target therapy at ESMOGI24.
The new NSCLC by Arndt Vogel but what will it take to get the targeted therapies into the 1st line setting like driver oncogene addicted NSCLC?
Is chemoIO is less efficacious in patients with driver alterations?
Fantastic discussion on localized biliary cancers – surgical and therapeutic approaches. Multidisciplinary management is key.
I am extremely happy and honored that we can shape here in Munich the future of education and research in GI cancer with ESMO, the ESMO community and ESMO’s great staff, with the scientific committee, with many colleagues and friends and with my co-chairs Teresa and Michel.
Starting off the session! Should we revise American Joint Committee on Cancer staging for colon cancer with the inclusion of ctDNA MRD positivity? The data looks impressive and suggests we need to revise!
One of highlights of the ESMOGI24 for YOs.
- Opportunity for networking and mentorship
- Listen the journeys of giants of the field
- Discuss patient management with real-world cases”
Subgroup analysis on NETTER2 with PRRT vs high dose SSA in high Ki67.
NETs CONFIRMS activity in
- G2 and G3
- Pancreas and Small Bowel
Lowest ORR in Small Bowel, Short time to response, Patient selection (not chemo patients).
All young oncologist attending ESMOGI24. We have 3 amazing sessions specifically for you with these excellent speakers from around the world. Come and join us!
Great summary from Ryan Corcoran re targeting RAS. Similar single agent ORR G12Cinh PDAC compared w/ NSCLC, vs CRC which improves w/ addition anti-EGFR. Supports KRAS good target in PDAC …just need to progress in G12D.
Why are gastrointestinal cancer patients getting younger? Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract. Editorial by Andres Cervantes on ESMO Daily Reporter.
Outstanding presentation by Jenny Seligmann at ESMOGI24 about neoadjuvant strategies to modify the status quo in localized colon cancer. Academic research will be the key, sure!
Phase I study of the PKMYT1 inhibitor lunresertib in combination with FOLFIRI in advanced GI cancers.
- MINOTAUR study
- Interesting MOA, for 20% of patients with CCCN1 amp or mFBXW7 >synthetically lethality
- Acceptable safety, “promising” efficacy
A great presentation on biliary cancers by Arndt Vogel. Which chemo backbone if patient is cisplatin ineligible? Answer of audience:
Meta-analysis of chemo backbones compared to gem-cis. There are almost no chemo backbone better than Gem-Cis.
